Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
This article examines the evidence linking Wegovy to hives, explores risk factors, and provides practical guidance on managing potential allergic reactions in line with UK regulatory guidance from the MHRA and NICE recommendations
Treatment includes medicines that remove copper such as chelating agents (e.g
Because Wegovy is dosed specifically for weight loss (often at higher doses than Ozempic), appetite suppression can be more pronounced which makes hitting daily protein targets even more important and more challenging
Regular monitoring ensures adjustments for optimal balance and minimal side effects